Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Alphapharm Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (849)
Cancellation by sponsor (780)
Prescription medicine registration (54)
Cancellation or suspension (44)
Australian Public Assessment Report (AusPAR) (3)
Designation or determination (3)
Prescription medicine decision summary (2)
Section 14, TGO91 consent (1)

Date

2024 (18)
2023 (84)
2022 (230)
2021 (265)
2020 (113)
2019 (35)
2018 (66)
2017 (364)
2016 (34)
2015 (22)
2014 (48)
2013 (40)
2012 (61)
2011 (28)
2010 (46)
2009 (25)
2008 (10)
2007 (28)
2006 (6)
2005 (17)
2004 (15)
2003 (33)
2002 (15)
2001 (4)
2000 (14)
1999 (9)
1998 (8)
1997 (11)
1996 (10)
1995 (7)
1994 (6)
1993 (12)
1992 (11)
1991 (41)

Results for "[search-keyword]"

Search

Sponsor content

1736 result(s) found, displaying 291 to 300

ARIMA moclobemide 150mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

24 January 2022

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
ARTHREXIN indometacin 25mg capsule blister pack Cancelled under Section 30(1)(c) of the Act

24 January 2022

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
GEMCITABINE-GA gemcitabine hydrochloride 1000 mg/100 mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

24 January 2022

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
GEMCITABINE-GA gemcitabine (as hydrochloride) 200 mg/20 mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

24 January 2022

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
LAMIVUDINE 150mg + ZIDOVUDINE 300mg ALPHAPHARM lamivudine 150 mg / zidovudine 300 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

24 January 2022

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
NEVIRAPINE ALPHAPHARM nevirapine 200 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

24 January 2022

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
GEMCITABINE ALPHAPHARM gemcitabine (as hydrochloride) 2000 mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

24 January 2022

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
GEMCITABINE ALPHAPHARM gemcitabine (as hydrochloride) 1000 mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

24 January 2022

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
GEMCITABINE ALPHAPHARM gemcitabine (as hydrochloride) 200 mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

24 January 2022

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
GEMCITABINE AG gemcitabine (as hydrochloride) 2 g powder for injection vial Cancelled under Section 30(1)(c) of the Act

24 January 2022

Cancellation by sponsor

Requested by Alphapharm Pty Ltd

Pages

First page
Previous page
…
Page 26
Page 27
Page 28
Page 29
Current page 30
Page 31
Page 32
Page 33
Page 34
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.